Environmental, Social And Governance Report

Overview

The report covers Alphamab Oncology and its subsidiaries for 2021. It highlights NMPA approval and commercialization of ENWEIDA, described as the world's first subcutaneously injected PD-L1 inhibitor approved for commercialization. Year-end headcount was 459 employees. Total GHG emissions were 9,920.39 tonnes, comprising 2,868.37 tonnes Scope 1 and 7,052.02 tonnes Scope 2.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2021
Period: 1 January 2021 – 31 December 2021
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services